WEBULL
WebtradeDownload

Is LifeStance Health Group (LFST) Undervalued As It Expands Esketamine And TMS Access?

Simply Wall St · 2d ago

LifeStance Health Group (LFST) stock is in focus after the company expanded access to esketamine and transcranial magnetic stimulation for treatment resistant depression, supported by internal data on symptom and suicidal ideation reductions.

The latest product update comes after a powerful run in LifeStance Health Group’s shares, with a 90 day share price return of 27.9% and a year to date share price gain of 92.5%, alongside a 1 year total shareholder return of 173.5%. This points to strong positive momentum despite a modest 1 day share price decline of 1.7% and some recent short term volatility.

Scan beyond LifeStance Health Group and see how other mental health and healthcare players with stronger balance sheets line up in our curated list of solid balance sheet and fundamentals (25 results) for comparison.

After a sharp rerating and only a small discount to analyst targets, LifeStance Health Group now trades at a more demanding price. Does that profile still offer enough potential upside to justify the risk for new buyers?

Most Popular Narrative: 24% Undervalued

On the most followed narrative, LifeStance Health Group’s fair value of $17.65 sits above the latest $13.40 close. This puts the current rally in a different light for anyone focused on long term potential rather than just recent momentum.

The buildout of higher-acuity services such as neuropsych testing, TMS, and Spravato, which are expected to move from roughly US$50 million of revenue in 2025 to about US$70 million in 2026, could shift mix toward offerings with richer economics and lift margins and earnings power as these services scale through the existing patient base.

See why 0 investors see LifeStance Health Group as 24% undervalued.

Result: Fair Value of $17.65 (UNDERVALUED)

Still, LifeStance Health Group carries real execution risk if higher G&A spending and historically weak free cash flow do not translate into stronger margins and returns.

Find out about the key risks to this LifeStance Health Group narrative.

Another View: What the P/E Ratio Says About LifeStance Health Group

The story looks different once the focus shifts from fair value models to the current P/E multiple. LifeStance Health Group trades on 101.2x earnings, compared with a peer average of 61.1x and a US Healthcare sector level of 25.3x, while the fair ratio is 42.7x. That gap points to meaningful valuation risk if sentiment cools or growth expectations change.

For a closer look at how this price compares with earnings power, take a look at the See what the numbers say about this price — find out in our valuation breakdown..

NasdaqGS:LFST P/E Ratio as at Oct 2026
NasdaqGS:LFST P/E Ratio as at Oct 2026

Next Steps

Plenty in this LifeStance Health Group story points in different directions, so move fast, review the detail, and weigh both sides of the argument with the 3 key rewards and 1 important warning sign.

Looking for more LifeStance Health Group sized ideas?

If you only stop at LifeStance Health Group, you risk missing other opportunities. Use the Simply Wall St screener to quickly spot fresh, high conviction ideas.

  • Target stability first and cut down portfolio stress by filtering for 30 resilient stocks with low risk scores built on resilient balance sheets and measured volatility profiles.
  • Hunt for quality at a discount and compare LifeStance Health Group with 18 high quality undiscovered gems that pair solid fundamentals with lower market attention.
  • Strengthen your income stream by reviewing 5 dividend fortresses that combine higher yields with robust cash generation and disciplined payout histories.